| TOP STORY | ‘Remote Control’ of Immune Cells Opens Door to Safer, More Precise Cancer Therapies Researchers engineered a molecular “on switch” that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments. [Press release from the University of California San Francisco discussing online prepublication in Science] Press Release | Abstract | Video | |
| SCIENCE NEWS | Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer Genentech announced early results from a pivotal Phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab in people with locally advanced or metastatic urothelial carcinoma. [Press release from Genentech, Inc. discussing research presented at the European Cancer Congress (ECC 2015), Vienna] Press Release OncoSec Announces Positive Results from Phase II Trial of ImmunoPulse™ IL-12 in Merkel Cell Carcinoma OncoSec Medical Incorporated announced results from a Phase II trial demonstrating that its investigational therapy, ImmunoPulse™ IL-12, promotes tumor-specific, systemic anti-tumor immune responses in patients with Merkel cell carcinoma. [Press release from OncoSec Medical Incorporated discussing research presented at the European Cancer Congress (ECC 2015), Vienna] Press Release New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (Pembrolizumab) Across a Range of Cancer Types Merck announced new findings from the KEYNOTE-028 Phase Ib study, the clinical trial investigating the use of the company’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. [Press release from Merck discussing research presented at the European Cancer Congress (ECC 2015), Vienna] Press Release Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Presented Genentech announced positive results from two Phase II studies that evaluated the investigational cancer immunotherapy atezolizumab in people with advanced non-small cell lung cancer. [Press release from Genentech, Inc. discussing research presented at the European Cancer Congress (ECC 2015), Vienna] Press Release Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure’s Novel AAV5-Based Gene Therapy uniQure N.V. announced the topline results of one-year follow-up data from a Phase I/II clinical trial conducted by Institut Pasteur in partnership with the French Muscular Dystrophy Association and Vaincre les Maladies Lysosomales in four Sanfilippo B syndrome patients treated with a novel gene therapy, AMT-110. [Press release from uniQure N.V. discussing research presented at the European Society of Gene and Cell Therapy (ESGCT) and Finnish Society of Gene Therapy (FSGT) Collaborative Congress, Helsinki] Press Release AlloCSC-01 Phase I Data Presented TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced that the CAREMI dose-escalation open-label phase data were presented. [Press release from TiGenix NV (GlobeNewswire, Inc.) discussing research presented at the 2015 Congress of the European Society of Cardiology (ESC), London] Press Release Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development Dr. Francisco Leon, CEO and Chief Medical Officer, will discuss the characteristics and mechanism of action of several investigational non-dietary treatments for celiac disease and gluten-related conditions, including AMG 714, a Phase II-stage, anti-IL-15 monoclonal antibody that Celimmune is developing for the treatment of diet non-responsive celiac disease and refractory celiac disease type II. [Press release from Celimmune LLC (PR Newswire Association LLC) discussing research to be presented at the Kansas City Gluten & Allergen-Free Wellness Event, Overland Park] Press Release Cellular Biomedicine Group Announces Positive Results from CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients with Solid Tumors Cellular Biomedicine Group Inc. announced results from an expanded Phase I/II clinical trial evaluating the safety, feasibility and anti-tumor activity of its chimeric antigen receptor-modified T-cells (CAR-T) immunotherapy targeting wild type EGFR (epidermal growth factor receptor) for the treatment of patients with EGFR expressing advanced relapsed/refractory solid tumors. [Press release from Cellular Biomedicine Group Inc. (GlobeNewswire, Inc.) discussing research presented at the 5th World Congress on Cancer Therapy, Atlanta] Press Release From our sponsor: Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM. Watch the webinar. |
| POLICY | New U.S. Board Proposed to Tackle Regulatory Burden on Research Universities The best way to ease the regulatory burden on U.S. academic researchers is to create another layer of bureaucracy. That surprising conclusion is the top recommendation in a report by a National Academies committee that Congress asked to examine the current regulatory jungle confronting universities that receive federal research dollars. [ScienceInsider] Editorial STAP Revisited Nature revisited one of the most controversial scientific episodes in recent years: the now-retracted discovery of a claimed new way to reprogram cells, stimulus-triggered acquisition of pluripotency (STAP). [Nature News] Editorial |
| BUSINESS | $25 Million for UQ Genomics Research A $25 million boost to genomics research at Queensland research institutions will help experts in their efforts to improve healthcare. The State Government announced new funding for genomics research today at The University of Queensland (UQ). [The University of Queensland] Press Release Arrowhead Reports Peak Reduction in HBsAg of Up to 99% after a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase IIa Study Arrowhead Research Corporation discussed top-line findings from the Heparc-2001 Phase IIa clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection. [Arrowhead Research Corporation] Press Release Syndax and Merck Announce First Patients Dosed in Phase Ib/II Clinical Trial of Entinostat and KEYTRUDA® Syndax Pharmaceuticals, Inc. and Merck announced the dosing of the first patients in the Phase Ib/II clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer or melanoma. [Merck] Press Release ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase III Registration Program in Glioblastoma ImmunoCellular Therapeutics, Ltd. announced that the governing Board of the CIRM has awarded the company $19.9 million to support the ICT-107 Phase III registration trial in patients with newly diagnosed glioblastoma. [ImmunoCellular Therapeutics, Ltd.] Press Release RuiYi Announces the First Human Dosing of a Novel Antibody, Gerilimzumab, for the Treatment of Rheumatoid Arthritis and other Autoimmune Disorders RuiYi, Inc. announced the first human dosing of Gerilimzumab, a novel monoclonal antibody that is directed against the IL-6 cytokine, for the treatment of autoimmune disorders, including rheumatoid arthritis. [RuiYi, Inc.] Press Release Merck KGaA and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma Merck KGaA and Pfizer announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab for the treatment of Merkel cell carcinoma, a rare and aggressive type of skin cancer. [Pfizer Inc.] Press Release Macrophage Therapeutics Produces First Two Immunoconstructs Macrophage Therapeutics, Inc. announced that it has developed a process for producing the first two therapeutic Manocept™ immunoconstructs, MT-1001, designed to specifically target and kill activated CD206+ macrophages and MT-2001, designed to inhibit the inflammatory activity of activated CD206+ macrophages. [Navidea Biopharmaceuticals, Inc.] Press Release Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has accepted for filing and review a supplemental biologics license application for the Opdivo+Yervoy regimen to include clinical data from CheckMate -067, a landmark trial in patients with previously untreated advanced melanoma. [Bristol-Myers Squibb Company] Press Release Sorrento Therapeutics and City of Hope Announce Exclusive License to Develop First-in-Class Immunotherapies against Intracellular Targets Sorrento Therapeutics, Inc. announced that they have formed a new company – named LA Cell, Inc. (LA Cell) – to focus on the development of cell-penetrating antibody therapies. LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies to penetrate into cells and target “undruggable” disease-causing molecules. [Sorrento Therapeutics, Inc.] Press Release RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 RXi Pharmaceuticals Corporation announced that it has been granted a patent from the State Intellectual Property Office of the People’s Republic of China for the composition and methods of use for RXI-109 and other connective tissue growth factor targeting self-delivering RNAi compounds for the treatment of fibrotic disorders, including skin fibrosis. [RXi Pharmaceuticals Corporation] Press Release |
| EVENTS | NEW Cell Culture 2016 February 2-4, 2016 London, United Kingdom Visit our events page to see a complete list of events in the cell, gene and immunotherapy community. |
|